Ligand Pharma (LGND) PT Raised to $345 at RBC Capital
Tweet
Share
E-mailGet Alerts LGND Hot Sheet
Price: $285.60 -1.43%
Rating Summary:
15 Buy, 5 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 9 | Down: 7 | New: 5
Rating Summary:
15 Buy, 5 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 9 | Down: 7 | New: 5
Join SI Premium – FREE
RBC Capital analyst Douglas Miehm raised the price target on Ligand Pharma (NASDAQ: LGND) to $345.00 (from $340.00) while maintaining a Outperform rating.
You May Also Be Interested In
- Snowflake Inc. (SNOW) PT Raised to $450 at Freedom Broker
- Zscaler (ZS) PT Raised to $190 at FBN Securities
- Asana (ASAN) PT Raised to $10 at UBS, Neutral Rating Maintained on 'Full' Valuation
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
